Structure, Function, and Diversity of Class I Major  Histocompatibility Complex Molecules by Bjorkman, Pamela J. & Parham, Peter
Annu. Rev. Biochem. 1990. 59.’253-88
Copyright © 1990 by Annual Reviews Inc’. All rights reserved
STRUCTURE, FUNCTION, AND
DIVERSITY OF CLASS I MAJOR
HISTOCOMPATIBILITY COMPLEX
MOLECULES
Pamela J. Bjorkman
Division of Biology and Howard Hughes Medical Institute, California Institute of
Technology: Pasadena, California 91125
Peter Parham
Department of Cell Biology, Stanford University, Stanford, California 94305
KEY WORDS: MHC, HLA molecules, peptide binding, polymorphism, T cell recognition.
CONTENTS
INTRODUCTION ..................................................................................... 254
Class 1 MHC Polypeptides ...................................................................... 256
THE STRUCTURE OF HLA-A2 .................................................................. 257
Structural Overview .............................................................................. 257
Structure of the lg-like Domains ............................................................... 259
Structure of the c~I and e~e Domains .......................................................... 262Size of Peptides that Fit in the Site ........................................................... 267
SEQUENCE DIVERSITY IN CLASS I HLA HEAVY CHAINS ........................... 268
The c~ Domain .................................................................................... 275
The c~1 and cee Domains ......................................................................... 275
ANTIGENIC PEPTIDE MOTIFS AND THE CONFORMATION OF
BOUND PEPTIDES ..................................................................... 280
WHAT IS SEEN BY A TcR? ...................................................................... 281
A Model for How TcRs Bind to the Peptide-MHC omplex ............................. 282
253
0066-4154/90-0701-0253502.00
Annual Reviews
www.annualreviews.org/aronline
A
nn
u.
 R
ev
. B
io
ch
em
. 1
99
0.
59
:2
53
-2
88
. D
ow
nl
oa
de
d 
fro
m
 ar
jou
rna
ls.
an
nu
alr
ev
iew
s.o
rg
by
 C
A
LI
FO
RN
IA
 IN
ST
IT
U
TE
 O
F 
TE
CH
N
O
LO
G
Y
 o
n 
09
/0
8/
05
. F
or
 p
er
so
na
l u
se
 o
nl
y.
254 BJORKMAN & PARHAM
INTRODUCTION
Lymphocytes are the agents of antigenic specificity in the immune response.
They divide into two groups: B cells that make immunoglobulins (Igs), and 
cells that perform a heterogenous set of functions including help for B cells,
production of delayed-type hypersensitivity reactions, and the specific killing
of virus-infected cells. Igs are the sole source of B cell specificity, whereas
molecules from two diverse families of cell-surface glycoproteins, the T cell
receptors (TcRs) and the major histocompatibility complex (MHC) glycopro-
teins, are the key elements of specificity in the T cell response to foreign
antigens.
TcRs, in common with the Ig receptors of B cells, are products of somati-
cally rearranging genes and are clonally expressed (reviewed in Refs. 1, 2 and
M. M. Davis, this volume). There are, however, two important differences in
antigen recognition by these related groups of lymphocyte receptors. The first
is a difference in the type of antigenic determinant (epitope) recognized: TcRs
recognize short, linear, peptide determinants of 10-20 amino acids (3-5), the
generation of which usually requires unfolding and proteolytic fragmentation
("processing") of the antigenic protein (6). By contrast, Igs commonly 
teract with epitopes formed by the three-dimensional structure of native
proteins, although they can also be .raised against peptides. The second
difference in antigen recognition by Igs and TcRs is the involvement of a third
molecule that performs the role of "presenting" the antigen to the receptor.
For B cells such molecules do not exist; the antibody receptor forms a stable
bimolecular complex with the antigenic protein. For T cells, the antigenic
peptide must be bound by an MHC glycoprotein, and it is this complex of
MHC molecule plus peptide that forms the structure rccognized by the TcR.
MHC glycoproteins are thus peptide-binding proteins, and can be considered
as antigen-presenting molecules.
There are two structurally distinct, but related, families of MHC molecules
that present antigens to two subsets of T cells: Class I MHC molecules present
antigens to T cells that express the CD8 cell-surface glycoprotein, and class II
MHC molecules present antigens to T cells that express the CD4 cell-surface
glycoprotein (7, 8). Other less rigid distinctions between class I and II MHC
molecules are in the categories of antigen presented and in the functional
activities of the responding T cells. Class I molecules commonly present
peptides derived from endogenously synthesized proteins, such as viral com-
ponents produced upon virus infection, and result in the stimulation of
CD8-bearing cytotoxic (killer) T cells (9). On the other hand, class II mole-
cules generally present peptides derived from exogenously synthesized pro-
teins and stimulate CD4-bearing helper T cells (10). This specificity in the
antigens presented by class I and class II molecules is thought to result from
cellular segregation of the compartments or sites at which class I and class II
MHC molecules encounter peptide (11, 12) (Figure 
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CLASS I MHC MOLECULES 255
Pathways of Antigen Processing and Presentation
Class I/Endogenous Pathway \ Class [[ / Exogenous Pathway
Figure 1 Cartoon showing the cellular processing and presentation of antigens. Endogenous
proteins (e-e-e) are degraded into peptides (e), which are bound by class I MHC molecules (open
triangles) in the endoplasmic reticulum (ER), and thus transported through the Golgi to 
plasma membrane (PM). Exogenous antigens (o-o-o) enter the cell by endocytosis and 
degraded in endosomal (En) and lysosomal compartments (Ly). Peptides (o) encounter class 
MHC molecules (filled-in triangles) in a poorly defined cellular compartment before transport 
the plasma n~tembrane. The invariant chain (open rectangle) transiently associates with class 
MHC molecules during exocytosis.
That T cells have a dual requirement for recognition of both foreign antigen
and a self-MHC molecule was first recognized by cellular immunologists in
the early 1970s (13, 14): T cell recognition of antigen became known 
"MHC restricted," with considerable debate focussing upon its molecular
interpretatiion and whether one or two receptor molecules were involved (15).
Transfection experiments have now demonstrated that a single TcR recog-
nizes both foreign antigen and MHC molecule (16). Discovery of the T cell
requirement for fragmented protein antigens led to investigation of the antigen
processing pathway, and revealed that incubation of antigen-presenting cells
with short peptides circumvented the need for processing and provided the
necessary target for the TcR (3, 17). Combining the concepts of MHC
restriction and antigen processing led to the hypothesis that MHC molecules
actually bind processed antigen fragments, thereby forming ligands for TcRs.
The first direct evidence for this model came with the demonstration of
binding of specific antigen peptides from hen egg lysozyme to a murine class
II MHC molecule (18).
The experiments that defined and characterized MHC restriction were only
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256 BJORKMAN & PARHAM
possible because MHC genes are polymorphic, with the products of different
alleles being distinguishable by both antibodies and TcRs. Indeed, alloreac-
tive responses in which the immune system of one individual makes antibod-
ies and T cells specific for the MHC molecules of another, are the basis for the
immunological rejection of transplanted tissues that led to the discovery of the
Major Histocompatibility Complex (19). The number of alleles at MHC loci
and the complexity of their patterns of substitutions are unique when com-
pared to other mammalian genes, and the basis for this diversity and its
functional significance are long-standing questions (20). Analyses of MHC
restriction (14), of T cell epitopes (5), and of peptide binding (21) all 
that polymorphic differences between MHC proteins affected the peptide
antigens presented and the T cells that could respond. Characterization of
MHC alleles revealed specific regions of the encoded protein at which
sequence diversity was concentrated (22), and the marked predominance 
coding over silent substitutions within those regions strongly suggested that
diversification was the result of natural selection (23, 24).
A model for how MHC restriction might work was eventually developed
(15, 25): a TcR was postulated to interact with a complex of a peptide bound
to a particular class I or class I1 MHC molecule, and a T cell selected by one
combination of peptide plus MHC would only be restimulated by that same or
a closely related peptide-MHC complex. The specificity of restriction would
then result from sequence variability in the MHC molecule, which determines
both the peptides capable of binding and the TcR selected. Determination of
the three-dimensional structure of HLA-A2, a human class I MHC molecule
(26, 27), has confirmed the general principles of this model and revealed
considerable insight into the details of the molecular interactions involved and
of the role played by MHC polymorphism. In addition, the structure has
helped to rationalize the kinetics of peptide binding to MHC molecules and
the inaccessibility of the site in all but a fraction of purified MHC molecules
(28, 29). More importantly, it has provided a mechanistic understanding 
immunological tolerance--the discrimination between self and nonself-~
which is arguably the most fundamental property of the immune system.
This review is focussed on the three-dimensional structure of HLA-A2 and
its interpretation in terms of the diversity of human class I MHC molecules,
and their interactions with peptides, TcRs, and the CD8 glycoprotein. Some
of the conclusions, but undoubtedly not all, will extend to class II MHC
molecules.
Class I MHC Polypeptides
Class I MHC molecules are noncovalently linked heterodimers (30). The
heavy chain (44 kd) is encoded within the MHC and spans the membrane
bilayer, oriented with its N-terminal major portion on the outside of the cell.
The extracellular portion of the heavy chain has been divided into three
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CLASS I MHC MOLECULES 257
domains called 0/~, 0/2, and 0/3 (31), composed of 90, 92, and 92 amino acids,
respectively, and encoded by separate exons (32). Following the 0/3 domain is
a membrane-spanning region of --25 amino acids and a cytoplasmic tail of
--30 amino acids. The light chain is a non-MHC-encoded protein called
fl2-microglobulin (fl2m, 12 kd) (33, 34). Both the 0/3 and/32m domains 
sequence similarity to Ig constant regions (31, 35, 36, 37), and are therefore
members of the Ig gene superfamily, which includes TcRs and class II
histocompatibility antigens (38, 39). Most amino acid substitutions between
the products of different class I alleles are localized to the 0/1 and 0/2 domains
with the 0/3 domain being relatively conserved, and f12 m invariant (22, 40).
Since the sequence differences that result in restricted recognition by T cells
and the differential ability to bind peptides mainly cluster in the O~1 and a:
domains, it was expected that these domains would comprise the part of the
molecule that binds peptides and is contacted by a TcR.
THE STRUCTURE OF HLA-A2
The three-dimensional structure of HLA-A2 was determined using X-ray
crystallographic techniques (26, 27). Prior to crystallization, the molecule
was purified after papain cleavage from the cell membranes of the
homozygous human lymphoblastoid cell line JY (41, 42). Papain cleaves the
HLA heavy chain 13 residues before the transmembrane region (43), yielding
a soluble heterodimeric fragment that retains all the serologically detected
epitopes of the native cell-surface molecule. The soluble form of HLA-A2
crystallized in two closely related space groups, and isomorphous crystals of a
second human class I MHC molecule, HLA-Aw68, were also obtained (44,
45). Both crystal forms grew as very thin (--20 to 100/zm) plates. Data from
crystals of one space group were collected using high-intensity X-rays from
synchrotron sources (46), which allowed the chain tracing of --90% of the
backbone of HLA-A2. The remainder of the structure was traced after averag-
ing electron density maps derived from the two HLA-A2 space groups (26;
M. A. Saper et al, manuscript in preparation). The structure of HLA-A2 has
now been refined to 2.6 /~ resolution (M. A. Saper et al, manuscript in
preparation; 47), and the structure of HLA-Aw68 has been solved and refined
to 2.6 ~ resolution (48). HLA-A2 and HLA-Aw68 differ by 13 amino acids; 
in the 0/~ domain, 6 in the 0/2 domain, and 1 in the 0/3 domain (49). The
0/-carbon backbones of the two molecules are very similar (48); thus, the
following description of the structure of HLA-A2 applies to HLA-Aw68, and
presumably to other class I MHC molecules as well.
Structural Overview
The HLA-A2 molecule is composed of two sets of structurally homologous
domains; one set being the membrane-proximal 0/3 and/3am domains, and the
other set being the membrane-distal al and 0/~ domains (Figure 2). 
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258 BJORKMAN & PARHAM
A. B,
TCR recognition region
r~
peptide ~t2
~2m
Figure 2 Schematic illustrations of HLA-A2 structure. ~3-strands shown as thick arrows,
o~-helices represented as helical ribbons. Amino and carboxy termini of the heavy and light chains
are indicated as "N" and "C." Disulfide bonds indicated as two connecting spheres. Figures
modified from Ref. 26 and prepared with the aid of a program described in Ref. 126. (a) The four
domains viewed from the side. The approximate location of residues 227 and 245 (implicated in
CD8 binding) indicated with small arrows. (b) The molecule has been rotated ° from the
orientation in Figure 2a. (c) The ~ and 2 domains asviewed from thetop of t he molecule
showing the peptide-binding site and surface presumably contacted by a TcR. (d) Carbon-o~ atoms
of the I~1 and ~2 domains with residue numbers.
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CLASS I MHC MOLECULES 259
anticipated from their primary sequences (31, 35, 37), the a3 and ~32m
domains are folded into /3-sandwich structures resembling Ig constant re-
gions. However, these Ig domains interact with each other in a novel arrange-
ment that has not been found in any of the known antibody structures
including Fcs, Fabs, or light chain dimers (50, 51). The common fold of the
a~ and a2 domains does not resemble an Ig variable or constant region,
although a:2 contains a disulfide bond reminiscent of those found in typical Ig
domains. The a~ and a2 domains sit on top of the Ig-like domains forming a
"platform" consisting of an eight-stranded/3-pleated sheet topped by two long
a-helices that lie diagonally across the sheet. The extracellular portion of the
molecule i,.~ about 70 ~ high (as oriented in Figure 2a), and cross-sectional
dimensions are about 50 ~ and 40/~,. Several lines of evidence suggest that
the binding; site for antigenic peptides is a deep cleft located between the two
long a-helices (27).
Structure of the 1g-like Domains
The/3-sandwich structure of the a3 and/32m domains are each composed of
two antipa~rallel/3-pleated sheets connected by an internal disulfide bond, as
shown schematically in Figure 3. One sheet has four /3-strands, while the
other sheet has three. Both MHC Ig-likc domains closely resemble antibody
constant domains, with the regions of greatest similarity being located in the
seven /3-strands. The loops connecting these strands show some structural
differences; from those in antibody constant domains, an observation also
made fron~t a comparison of the structure of bovine/32m with an Ig constant
domain (5:2). As is common in/3-structure, extensive hydrogen bonding 
found between the main chain atoms of adjacent strands within each sheet.
HLA-A2, Aw68, and /3zm represent the first members of the Ig gene
superfamily, other than antibodies, for which three-dimensional structural
information is available. Because MHC molecules contain two Ig-like do-
mains, prior to determination of the three-dimensional structure it was gener-
ally assumed that the mode of subunit interaction in MHC molecules would be
the same as found in antibody structures. Antibody constant domains contact
each other with their four-stranded/3-pleated sheets together, and one domain
is related to the other by a dyad axis (a 180° rotation) of symmetry (50, 51).
This same subunit interaction is preserved in the CH-CL pair of an Fab, the
CH3 dimer in Fc, and the CL-CL dimer in a light chains dimer. It was
therefore a surprise to find that the two Ig-like domains in the HLA-A2
structure interact in a novel way not previously found relating pairs of
antibody domains. In the class I structure, c~3 is related to /32m by a 146°
rotation followed by a 13/~ translation along the rotation axis direction (26),
instead of the 180° rotation without a translation that relates pairs of antibody
domains. This interaction is unlikely to be an artifact caused by the packing of
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260 BJORKMAN & PARHAM
HLA molecules within the crystal, since it is found in both crystal forms of
HLA-A2, for which the packing of adjacent molecules differs. A schematic
view of a pair of antibody constant domains can be compared with the ot3-fl2m
pair in Figures 3a and 3b.
An examination of Figure 3a reveals that the a3 and/32m residues that are
involved in the contact interface are within their respective four-stranded
sheets, but the contact pairs are not symmetrical as would be found if the two
domains were related by a two-fold symmetry axis. There are more extensive
contacts between fl2m and the oq-a2 platform than between a3 and the
platform (26), because the effect of the 13 ,& translation that relates a3 and
/32m is to move /32m up, so that it supports the al-o~2 platform. Thus o~3
interacts extensively only with /32m, whereas /3~m interacts with all three
domains of the heavy chain. Circular dichroism experiments suggest that the
heavy chain of HLA loses its structure when separated from/32m (53), and
analysis of antigenic reactivity suggests that association with/32m is accom-
panied by substantial changes in the conformation of the heavy chain (54-56).
Association with/32m also appears to be required for cell-surface expression
of HLA class I heavy chains (57, 58), although one murine class I heavy chain
(H-2Dd) can be detected in small quantities at the surface of cells in the
absence of /32m (56). These studies indicated that association with /32m
facilitates or stabilizes the folding of class I heavy chains during biosynthesis
(59), an idea substantiated by the way in which/32m contacts all three heavy
chain domains in the HLA-2 structure. Furthermore, studies of mutant cell
lines defective in association of/32m and class I heavy chains have shown that
binding of an appropriate peptide may be critical for correct folding of the
heavy chain, association with ¢32m, and transport of the complex to tile cell
surface (60).
The HLA-A2 structure shows that the presence of a pair of Ig-like domains
in a molecule need not necessarily imply an association between those
domains that is similar to that found in antibodies. As crystal structures of
other members of the Ig superfamily are determined, additional ways for pairs
of antibody domains to interact may be found. It will be especially interesting
to see if the novel mode of association of the Ig-like domains in class I
molecules is preserved in a class II MHC structure, in which there are two
membrane-associated polypeptides (~ and/3), each having one Ig-like domain
and one domain similar to either cq or ~ of the class I heavy chains (61).
CD8 INTERACTS WITH THE 0/3 DOMAIN The mature T lymphocytes that
have receptors recognizing class I MHC molecules invariably express the
CD8 glycoprotein (7). This molecule exists as a homodimer of c~ chains, or 
heterodimer of c~ and/3 chains. The striking correlation between CD8 expres-
sion and class I MHC restriction of a T cell’s receptor led to the
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CLASS I MHC MOLECULES 261
1:3.
CH3
CH3
Figure 3 Comparison of the interaction of the a~ and ~3zm domains of class I MHC molecules
(3a) with that of two Ig constant domains (3b). Constant domains are the two CH3 domains 
Fc (127). The two Ig domains in HLA-A2 are paired in an interaction not found relating pairs 
antibody con,,;tant domains. Prepared with a program described in Ref. 126.
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262 BJORKMAN & PARHAM
hypothesis that there is specific biological interaction between class I MHC
molecules and CD8 (62). Many indirect observations provided support for
such interaction, which has been more directly demonstrated with an in vitro
cell-binding assay (63).
This assay also revealed that HLA-Aw68 is unlike other class I MHC
molecules, including HLA-A2, in that it does not bind, or has a highly
reduced affinity for, CD8 (64). In vitro mutagenesis showed that, of the 
amino acid differences between HLA-A2 and HLA-Aw68, a single substitu-
tion of the a3 domain at position 245 is solely responsible for the change in
CD8 binding. The structures of the a carbon backbones of A2 and Aw68 are
very similar, and it is likely that the change of side chain--alanine in A2 to
valine in Aw68---is responsible for the difference, and that this region of the
a3 domain is directly involved in the interaction with CD8 (48).
Independent evidence for this model comes from study of a mutant mouse
class I MHC molecule that was selected for loss of a monoclonal antibody--
defined epitope of the a3 domain (65). In this mutant H-2Dd molecule,
glutamic acid at position 227 is replaced by lysine. Extensive analyses of the
capacity of T cells to recognize this mutant molecule indicate that it has lost
the capacity to interact with CD8 (66). Residue 227 is an exposed residue
found on the loop between strands 3 and 4 of the Ig fold of a3, whereas
residue 245 is on strand 5 of the fold and is only partially exposed. These two
residues are only 10.5 ,~ apart and could easily form part of a single
CD8-binding site. Comparison of other point mutations within the a3 domain
has identified further positions within the loop between strands 3 and 4 and in
strand 4 that affect CD8 binding. The loop (residues 220 to 229) contains five
acidic and no basic residues. Mutational analysis shows acidic groups are
important for CD8 binding, suggesting that the negatively charged loop may
be a central site of contact with CD8 (67).
It is of note that strands 4 and 5 of the a3 domain comprise the major site of"
interaction with/32-microglobulin (26). That substitutions within this region
also affect CD8 binding suggests that/32m may directly contribute to interac-
tion with CD8, and raises the possibility that the unique juxtaposition of the
Ig-like domains in class I MHC molecules is an adaptation to binding CD8.
Structure of the Ol. 1 and a2 Domains
The a~ and a2 domains have been the focus of most interest, because this part
of the HLA structure is responsible for peptide binding and MHCorestricted
recognition by TcRs. Although there is only minimal, if any, sequence
similarity between al and a2 (31), the two domains share a common tertiary
structure and probably a common origin. Each is composed of a four-stranded
antiparallel/3-pleated sheet that forms the amino-terminal half of the domain,
followed by a long a-helical region (Figures 2c, 2d, and 4). When a~ and 
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CLASS I MHC MOLECULES 263
are paired !in the HLA structure, they are related by a nearly exact two-fold
rotation axis, so that a single eight-stranded antiparallel fl-pleated sheet is
formed from the four-stranded sheets in each domain. The a-helices then lie
on top of the sheet running antiparallel to each other, their helical axes making
an angle of approximately 40° with respect to the /3-strands in the sheet.
The presence of approximate dyad symmetry relating two homologous
domains of a single polypeptide chain has been observed in other proteins in
which repetitive domains are suggested to have arisen by gene duplication,
resulting in the formation of a so-called "intramolecular dimer" (68). These
types of proteins are suggested to have evolved from two identical
polypeptides that formed a dimer with exact two-fold symmetry. If a gene
duplication occurred so that the two polypeptides were in series in a single
polypeptide chain, the resulting intramolecular dimer would be an acceptable
structure if the carboxyl end of one subunit was close to the amino end of the
other in thc original intermolecular dimer. The interface between domains in
the intramolecular dimer should require few changes, since the two halves had
evolved to fit together in the original dimer. Examples of proteins that may
have evolved this way include ferredoxin, parvalbumin, and pepsin (68), 
well as the: al and a2 domains of class I MHC molecules. The N-terminal
domains of class II MHC ct and/3 subunits are hypothesized to be structurally
similar to class I aj and a2 (69), which as a pseudo intermolecular dimer, may
represent an intermediate in the evolution of the class I MHC peptide-binding
region. It is also interesting to note that in almost all symmetric multidomain
enzymes o:r binding proteins as well as in the MHC a~ and a2 domains, the
active center is located at the interface between domains, and close to the
symmetry axis relating them (68).
The helical regions of both the al and a2 domains are composed of two
a-helices. The first helix in a~ is a short helix of -11/2 turns (residues 50-55)
that meets a longer helix of 71/2 to 8 turns (residues 57-85) at an angle 
approxima~Iely 110°. The a2 domain’s helical region also starts with a short
helix (residues 138-148; -3 helical turns) that meets a longer helix (residues
150-175, ~71/2 helical turns) at an approximate angle of 130°. The short
helices at the amino-termini of the helical regions in al and a2 form the means
by which the floor of the domain (i.e. the/3-pleated sheet) is linked with the
top of the domain (the long helices). The long helices of c~1 and az are
respectively in length about 41 ~, and 37/~, and are located about 18 ,~ apart
(as measured between the a-carbon atoms of residues 67 and 160). The mean
interaxial distance for two helices placed next to each other is 9.4 .~, (70);
thus, there is an obvious gap between the two MHC a-helices, which has been
hypothesized to be the site where antigenic peptides bind (27). The axes of the
two long helices make an angle of approximately 20° with respect to each
other, so that in both cases, the amino-terminal residues of these helices
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264 BJORKMAN & PARHAM
project to the highest points of the molecule, and may therefore be the most
accessible residues to a TcR recognizing the top surface of peptide-MHC
complex. A view of the molecule that illustrates this point is shown in Figure
2b.
LOCATION FTHE BINDING SITE FOR ANTIGENIC PEPTIDES The large cleft
between the a-helices is the most likely location of the single.peptide-binding
site proposed on the basis of peptide competition experiments (21). In addi-
tion to the obvious fact that the cleft is on the top surface of the molecule
where it would be easily accessible to TcRs, there are other supporting lines
of evidence:
1. The HLA-A2 crystal structure shows an unknown molecule or mixture of
molecules to be occupying this site, presumably representing peptide(s)
that copurified and cocrystallized with the HLA protein. The fact that
molecules in the site remained bound during the entire purification pro-
cedure is consistent with the slow kinetic off-rate observed for peptides
bound to class II MHC molecules (71).
2. The site has a size and shape consistent with accommodation of peptides of
the size known either to bind to MHC molecules, or to be recognized by T
cells after incubation with target cells (5, 72). [A peptide of 12-20
residues in an a-helical conformation could fit into the groove although,
depending upon the amino acid side chains, the fit could be quite tight.
Alternatively, the site could accommodate about eight residues of peptide
in an extended conformation (27). Longer peptides or even extended loops
of proteins could bind to the site if they protruded over one or both ends of
the site.]
3. Much of the sequence variation between HLA-A,B,C molecules (Figure
4) is found in residues that line the sides and bottom of the groove (27).
This finding correlates with and provides a molecular mechanism for the
observed specificity in peptide binding to different allelic products. In
particular, 18 of the 20 positions with high variability in amino acids have
side chains that point into the groove and potentially alter peptide binding,
and 10 of the 13 substitutions that distinguish HLA-A2 and HLA-A28 are
in such positions.
4. Residues known to affect recognition of class I MHC molecules by T cell
clones fall in the site in positions where they could make direct contacts
with bound peptides or with a TcR recognizing the peptide-MHC complex
(27).
The floor of the peptide-binding site is formed by residues on the first and
second /3-strands of the a~ and az domains whose side chains point "up"
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CLASS I MHC MOLECULES 265
(direction defined by Figure 2a), and its sides are formed by residues on the
two a-helices that point "in," toward the site. The residues on the floor and
sides of the site with inward-pointing side chains have been classified as
potentially interacting with peptides (downward-facing triangles in Figure 4),
and candidates for direct recognition by TcRs if they are located on one of the
two a-helices and their side chains point "up" (upward-facing triangles in
Figure 4). Residues with side chains in an intermediate position between "up"
and "in" could interact with either peptides or TcRs (diamonds in Figure 4)
(Ref. 27).
IS THE MI-][C PEPTIDE-BINDING SITE ALWAYS OCCUPIED? An important
implication of the occupation of the binding site in the HLA-A2 crystal
structure is that cell-surface MHC molecules may always be filled with
endogenous peptides derived from "self"-proteins. The presentation of
"self"-peptiides in addition to "foreign" peptides had been postulated by
various authors (73, 74). The studies of Townsend et al (60), suggesting 
peptide bin,cling is essential for correct folding of the heavy chain and trans-
port to the cell surface, would support this hypothesis, as does the finding of a
heterogeneous mixture of peptide material associated with purified class II
MHC molecules that can be released by treatment at pH 2.5 (Ref. 28). 
therefore seems likely that any preparation of purified class I or class II MHC
molecules will contain bound peptides, and that in vitro peptide-binding
studies have been largely measuring the binding of exogenous peptide only
after displacement of endogenous material. This may explain the small frac-
tion of MHC molecules--5-10% for purified class II MHC molecules (28)
and 0.3% for class I MHC (29)--with sites accessible to an experimental
peptide. The slow on-rate observed for peptide binding to class II MHC
molecules (71) could also be due to the necessity for displacement 
endogenous, material before binding.
It is probably not necessary that endogenous peptide be displaced from
every surface MHC molecule on a cell before T cell recognition occurs, but it
is not known what percentage of surface MHC molecules must be occupied by
a foreign peptide to trigger a T cell response.
Presentation of self-peptides and immunological tolerance A current view is
that assembly and cell-surface expression of class I MHC molecules requires
binding of peptides, a process that occurs in the endoplasmic reticulum (60).
The peptides presumably derive from endogenous proteins through routine
processes of intracellular degradation and turnover. Although little is known
of the parameters determining which peptides are presented, they are likely to
include the concentrations of peptides, the specificity of systems that transport
peptides into the endoplasmic reticulum, and the residues in the combining
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266 BJORKMAN & PARHAM
site of the class I heavy chains. In a healthy cell, the class I MHC molecules at
the plasma membrane will display a selection of peptides derived from
self-proteins that do not provoke an aggressive T cell response, because the
immune system develops a state of nonresponsiveness or tolerance to self
during ontogeny. When that same cell is infected with a virus, viral peptides
will compete with endogenous peptides for binding to class I MHC mole-
cules. When presented at the cell surface, they will be recognized as foreign
and stimulate an aggressive T cell response (9).
In vivo, class II molecules do not bind the same spectrum of peptides as
class I molecules (75). This difference is not just the result of differences 
combining site specificity, but of distinct intracellular pathways for peptide
binding (Figure 1). Although class II o~ and fl polypeptides are synthesized
and assembled in the endoplasmic reticulum, they do not appear to bind the
peptides they will present until reaching a site where peptides from ex-
ogenous, endocytosed proteins predominate over those from endogenous
proteins. The mechanistic basis for this difference is not understood, but
probably involves the invariant chain protein, which shows a specific but
temporary association with class II molecules during their protracted transit
from the endoplasmic reticulum to the plasma membrane (76). One possibility
is that part of the invariant chain fills the groove of the class II molecule,
acting as a keeper peptide, during passage from the endoplasmic reticulum to
the peptide-binding compartment.
That self-peptides are bound by MHC molecules and brought to cell
surfaces is indicated by studies of Lorentz & Allen (77, 78). They isolated 
cell hybridomas from mice immunized with an allelic form of hemoglobin,
and showed that self-hemoglobin peptides were presented by class II MHC-
bearing cells in the strain of mice that was immunized. Thus, there appear to
be no specific mechanisms for distinguishing self from nonself at the level of
peptides binding to MHC molecules and being expressed at the cell surface.
Evidence points to the discrimination between self and nonself being
exercised at the level of the T cell, with MHC and peptide presentation
contributing to the selection and control of the TcR repertoire. T cells mature
in the thymus gland; it is there that rearrangement and expression of TcR
genes occurs and where a small fraction of the receptor-bearing cells are
selected for differentiation into mature, circulating peripheral T cells (4, 79).
In essence, selection is a matching of TcRs against the class I and II MHC
molecules of the individual, and evidence has accumulated to invoke both
positive and negative elements. Within the thymus, the TcRs of immature T
cells are exposed to class I and II molecules complexed with peptides derived
from endogenous proteins from thymic ceils, and from proteins derived from
other cells that are taken up by thymic cells (4, 79, 80). Potentially auto-
reactive cells with receptors that interact too strongly with any of these
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CLASS I MHC MOLECULES 267
complexes are eliminated, and such clonal deletion is a major contributor to
self-tolerance (81-83). On the other hand, cells with a certain strength 
interaction with a self-MHC molecule, such that are not autoreactive but
would be stimulated by the complex of that MHC molecule with a foreign
peptide, are positively selected (8, 84).
Negative selection in the thymus explains tolerance to all thymic proteins,
which will include all housekeeping proteins, and to proteins such as those in
the blood that can be taken up by the thymic cells. For example, Lorentz &
Allen (78) found that thymic cortical epithelial cells presented the hemoglobin
self-antigen in fetal thymus during the period of time that selection against
self-reactiw. ¯ T cells is known to occur. There are, however, likely to be
specialized self-proteins that are processed and presented in certain cells and
tissues but not in the thymus. T cells with receptors specific for these MHC
peptide complexes will leave the thymus, and studies with transgenic mice
show that alternative mechanisms of peripheral tolerance exist to prevent
them from turning autoreactive (85). These mechanisms do not appear 
involve elimination but an inactivation of the T cells that requires continued
presentation of the antigen and may, on removal of antigens, be reversed and
lead to an autoimmune reaction.
Thus it is possible to explain both the selection and activation of T cells in
terms of the.. presentation of self- and foreign peptides at critical points in the
development of T cells. A consequence of this scheme is that tolerance will
~ot be induced against self-peptides that are not bound by self-MHC mole-
cules.
Size of Peptides That Fit in the Site
From the size of the HLA-A2 peptide-binding site, it appears that for bound
peptides longer than 20 residues, one or both ends would have to extend
beyond the site. It is known that lysozyme (86), ribonuclease (87), 
myoglobin (88) can bind to class II MHC molecules and be presented 
unfolded, but intact polypeptide chains, suggesting that in these cases, the
peptide epit,3pe is binding with the rest of the polypeptide chain of the protein
protruding ,out of one or both ends of the site. These observations were
extended by a study in which a 34-residue lysozyme peptide was found to
bind to a class II MHC molecule without further proteolytic processing (89).
This peptide was synthesized with o-amino acid residues flanking the known
T cell epitope region, thus ensuring that the extra residues would not be
cleaved by any protease. The core residues involved in the T cell determinant
were protease sensitive unless bound to the class II molecule, demonstrating
that an MHC molecule can protect a determinant from proteolytic degrada-
tion, a finding that is consistent with the proposal that MHC molecules may
protect antigens from a total degradation during antigen processing (10).
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268 BJORKMAN & PARHAM
Human fibrinogen represents an example of a protein that does not require
processing (i.e. conversion into a peptide form that associates with an MHC
molecule), but will stimulate T cells when associated with class II MHC
molecules as an intact, and presumably native, protein (90). The fibrinogen
epitope that is recognized has been localized to a 27-amino-acid region near
the C-terminus of one of the chains, and is hypothesized to be a con-
formationally flexible portion capable of inserting into the peptide-binding
site.
Although we have primarily discussed the binding of peptide antigens to
MHC molecules, it is possible that nonpeptide molecules could bind to and be
presented by MHC molecules. The heme moiety of cytochrome c has recently
been shown to be a dominant MHC-~restricted T cell epitope (91). It has also
been suggested that the binding of nonpeptide organic compounds to MHC
molecules might play a role in the ability of mice or rats to distinguish
differences in MHC haplotypes of potential mates. Class I molecules are
excreted into urine, and rats can distinguish the smell of urine samples from
donors that differ genetically only at the class I MHC locus (92). It has been
proposed that different allelic class I products might associate with a unique
mixture of volatile, endogenous metabolites, leading to the ability to distin-
guish MHC haplotype by olfaction (92).
SEQUENCE DIVERSITY IN CLASS I HLA HEAVY
CHAINS
Diversity in the class I MHC molecules expressed by an individual is formed
by compounding factors. The first is that multiple, divergent heavy chain loci
are codominantly expressed. Their number varies between species and it can
also vary between individuals within a species (20, 93). Certain "classical"
class I MHC loci are expressed on a majority of cells types: in mice they are
the H-2L, K, and D loci, and in humans they are the HLA-A,B,C loci.
Products of other "nonclassical" class I genes exhibit restricted tissue distribu-
tions and can be either secreted, retained in the cell, or expressed at the cell
surface. Examples of "nonclassical" human class I genes are HLA-E, F, and
G (94). With few exceptions (95), class I molecules that present antigens 
cells are products of classical class I genes, and physiological functions for
the products of nonclassical class I genes have yet to be established. Even the
functionality of classical class I loci can pose problems; for example, HLA-C
shows a significantly reduced cell-surface expression compared to HLA-A and
B, and its capacity to present antigens to human T cells is uncertain.
The considerable variation in the numbers of class I genes and of expressed
class I genes provides evidence for evolutionary plasticity of the MHC and the
continuing production of new antigen-presenting genes coupled with elimina-
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CLASS I MHC MOLECULES 269
tion or inactivation of older genes. The HLA-AR pseudogene provides an
example of a product of the latter process (32, 96). HLA-AR is closely linked
to HLA-A, and similarities to that gene suggest that HLA-A and HLA-AR were
the products of an ancestral gene duplication. Although HLA-AR sequences
are very similar to HLA-A,B,C, they have one or two nucleotide changes that
ensure this gene does not encode functional antigen-presenting heavy chains.
One point substitution changes the cysteine at position 164 that forms the
disulfide bond of the c~2 domain to phenylalanine, and a single nucleotide
deletion that produces a frameshift in the middle of exon 4 results in a
non-Ig-like sequence for o~3 accompanied by premature termination (Figure
4a). HLA-AR amino acid sequences are consistent with the idea that HLA-
AR proteins were used in the past for antigen presentation, but the gene was
subsequently inactivated and became a pseudogene. Accompanying this ab-
sence of contemporary function is a limited polymorphism and sequence
diversity, especially at positions that show high variability in HLA-A, B, or C
molecules.
The second factor that creates diversity in the classical class I MHC is their
Figure 4 Amino acid sequences of human class I HLA heavy chains. The consensus sequence is
from Ref. 22 and identities with the consensus are shown by a dash. Downward-facing triangles
designate residues postulated to interact with peptides, upward-facing triangles indicate residues
postulated to interact with TcRs, and diamonds indicate residues that are postulated to interact
with peptides and/or TcRs. These assignments are modifications of those described in Ref. 27,
taking into account he possibility that TcRs may interact with residues that point "up" and away
from the peptide-binding groove, in addition to those that point "up," or "up" and "in." The single
invariant site of N-linked carbohydrate addition at position 86 is shown by CHO. Residues of o~3
that are implicated in binding CD8 from in vitro mutagenesis experiments are shown with an
asterisk. The secondary structure is given below each domain sequence with /3 strands being
represented by arrows, helices by squiggles, and loops by straight lines. (a) c~ and z domains
of HLA-A, AR, E, F, and G. The HLA-A sequences are divided into five families as described
(128). Vertical lines show residues that are conserved in all HLA-A,B,C sequences. With the
exception of HLA-12.4, all HLA-AR alleles have a single nucleotide deletion in codon 227
(indicated by an X). For one sequence, 5.4-LBF, the consequences of the frameshift, including
termination i~t codon 272, are shown on line 5.4-LBF/fs; otherwise the HLA-AR sequences are
translated in the same reading frame as HLA-A,B,C. References for sequences are: HLA-E,F,G
(94); HLA-AR (22; P. D. Ennis et al, manuscript submitted; 96); A29, A30, A31, A33 (128,
129); A11K (130); A2 subtypes (98, 131, 132). (b) a~ and a2 domains of HLA-B. References
for sequences are: B37, B57 (22, 101; P. D. Ennis et al, manuscript submitted); B27 subtypes
(132); B51(W) (133); B51, Bw52 (134); B13.1 (135); B35 (136); B38, B39 (137); 
Takiguchi, personal communication). The new and old designation for B27 subtypes are given
(97). B? is ala as-yet-unassigned molecule that is related to Bw58. (c) 3 domains of HLA-A,AR,E,F,G, and B. (d) oq, ot~, and 3 sequences ofHLA-C molecules. References for
sequences are: Cwl, Cw2.1 (138); Cw2.2, Cwl I (101); Cw5, CwBLI8 (139); Cw6 (D) 
Cw6 (W), Cw7 (133); JY328 (141); CI.9, CI.10 (129); Cb-l, Cb-2 (142); BeWoC1 (143); 
(144); pC1 (145).
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A2/28 f
A1/3/11 f
A19 (
A9 C
I I0 20 30 40 50 60 70 80 ~90
A2.4b .... F .............................-Q ...........-G--RK---H---H-V D-G ...........
Aw69 ............................. q ................... N-RN ......... VD-, ...........
AW68 ¯  2 .......M .........................
-Q ..................N-RN- .......VD’-G ..........
A1 ..... F ...........................QK .............Q--RNM--H .....AN-G ..........D
A29o 1 ......T .......................-Q .................LQ-RN .........AN-G ...........
A33 ..... T .........................-Q ..................N-RN---H--I--VD-G ...........
~
A25 .................................q ...................N-RN---H .........IALR ......DA, 0 A267 ..................................7Q ................N-RN---H .....AN=G ..........D
5.4-LBF R .....TM ..........S .............D----E ......M-R .......N---C--AR-E--N--I ALR .....-(3
non ) HLA-E ....LK--H .............S ..........N .....V ....H----S .......RSARDTA-I F-VN .....R .......
consensus GSHSMRYFYTSV SRPGRGE PRF IAVGYVDDTQFVRFDS DAAS P RME P P4% PW I EQEG pEYWDRETQI VKAQS QTDRES LRTLRGYYNQS EA
10 20 30 40 50 60 70 80 90
A2/28 I
A1/3/11 I
A19 ~
100 II0 120 130 140 150 160 110 180
consensus GSHTLQF~MYGCDVG PDGRLLRGYHQYAYDGKDY IALNE DLRSWTAADTAAQ I QRKWEAARVAEQLRAYLEGTCVEWLRRYLE NG KETLQ A
A2.2Y ..........S-W-F ............K .......M--T-KH .....H--W ........................T
HLA-AR 5.4-LCL. 2 --M-V ..........F-C--E-H ...................M----K .......R---R-V----E F ---X ........K ....
classical"L HLA-F ....G-N---M ..........H .......S .........U ......FY--EEY--EF-T----E-L-L ...............
consensusGSHTLQRMYGCDV, P GRLLRGYHQYAYDGKDY IALNE DLRSWTAADTA,Q ITQRKWEAARVAEQLRAYLEGTCV EWLRRYLE NGKETLQRA
100 lI0 120 130 !40 150 160 170 180
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B35 ..........AM ................................, .........N---F-’rNr--Y .....N ..........
BSNA ..........A~I ................................T ........N---F-TNT ........N .........
B? .......... ~1 ................................ T ................ G--RNM--SA--Y--N--IALR .......
Bw57 .......... AM ................................. A ............... G--RNH--SA--Y--N--IALR
B’2702 ........ }l .............. T ....... L ............ E ..................... C--KA ..... N--IALR ....... B27o2
B’2704 ....... H .............. T ....... L ............ E ..................... C--go% .......... LR ....... B27.3
B’2706 ........ H .............. T ....... L ............ E ..................... C--~tA .......... LR ....... B27o~
B44.2 ..........AM ...........T .....L .......T---K .....................S-TNT--Y--N---ALR
B37 ........ }1 .............. S .................... , ..................... S-TNT--Y--D----LR
839 .......................S ...................E ............N---C~TNT .......N .........
Bw65 .......... A ............ S .................... E ................. N---C-TNT ........ N ........
BI4 ...................... S .................... E ................. N---C-TNT ........ N ........
818 .......H ..............s ..G .............. , .................N---S-TNT--Y .....N ..........
B40* ........ H .............. T ....... L ........ T---K .................... S-TNT--Y ..... N .........
Bw4 L ........ H-AM .......... T ....... L ....... T---K .................... $-TNT--Y .... N ..........
Bw60 ........H--AM ..........T .....L .......T---K .....................S-TNT--y .....N ..........B8 ........ D-AM ........... S .................... E ................. N---F-TNT ....... N
87.2 ..................... S ................... E ................. N---Y---A ........ N ..........
BW62 .......... AM ............................... A ................... S-TNT--Y ..... N
consensus ~SHSMRYFYTSVSRPGRGEPRF~AvGYVDDTQFVRFDSDAASPRMEPK~.P~EQEGPEYWDRETQ~VKAQSQTDRES~RTLRGYYNQ$EA
10 ~0 30 40 50 60 70 80 90
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A2/28 f
A1/3/11 I
190 200 210 220* ** *230* 240 250 260 270
consensus~PPKTHVT~HP~SDHEATLRCWALGFYPAE~TLTWQRDGEDQTQDTELVET~AC~TFQKWAA~V~PS~EEQRYT~HVQ~E~LPKPLTLRW
A2.4b
-A----M---AV .........S ............................-G .......Q ...................
A2-OZB -A----M---AV ...........$ ...........................E--~ .........Q ..................
A2.2F -A----M---AV ..........S ..........................0 ........Q ...................
Aw68. I -A----M---AV ........S ..........................G ......."~" 0 ..................
A3.2 S
-C
A30.3 ..... M .............................................. --G .................................
AIIK .....M ..............................................0 ...................................
aI ......M ...........................................0 ............................
A19 A31 .....M---AV ...........S .............................G S .....q ....................
A9 t ~,z4 ..... ~ .......................................... --G ...................................
a25 -^----H---av .........S ............................G .S .....q ...................
AI 0 A26? =A----M---AV ............S ...........................-G S .....Q ....................
JYB .....H ..............................HX---H ......~ ............................E 
HLA-AR 5.4-LCL.2 ....M .................................HX .........~ ..........................E
5. &-LBF ....H ..................................HX .G ..........................e 
consensus DPPKTHVTHH P l S DHEATLRCWALGFYPAE ITLTWQRDGE QTQDTE LVETRPAGDRTFQKWAAVVV PSGEEQRYTCHVQHEGL p KP LTLRW190 200 210 220 230 21.0 250 260 270
~3 domain ,190 200 210 220* ** *230* 240 250 260 220
consensus D~PK~HVTHHP~DHEATLRCWALGFYPAE~TLTWQR~G~QTQDT~LVETRPA~DRTFQ~W~A~VP$GEEQK¥T~Q~GLPK~LTLRW
B35 ....... v
BSNA V
BSI .... v
BSI (W) ...... V ..........................................................
Bw52 ...... V
Bw57 ..............................................................
B’2705
B’2702
~’2704 .......................................................................
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a3 domain . **. . .190 200 210 220 230 240 250 260 270
consensus DPPKTHVTHHPlSDHEATLRCWALGFYPAE~TLTWQRDGEDQTQDTELVETRPAGDRTFQK~AAVVVPSGEEQRYTCHVQHEGLPKPLTLRW
Cwl EH ........V ......................W .............-C ........M ..................E ......
C’w2. t E~ .........v ..............T .......................G .......................E 
Cw2.2 EH ........V ..............-T .......................-G ......................E 
Cw3 S~ ........V .......................W .............~ ............................E 
Cw5 EH ........V .........................................-~ ............................E 
Cw6 (D) E~ ....... ~-V .......................................... G ............................ E ......
Cw6 (W) EH .........V .......................................-G .....................E 
C~7 E .........L .........................................C .............q ....M ....QE-- -S-
JY328 E ..........L ..........................................G .............Q ....M ....QE ......
Cwll E~ ........V ...........................................C ............................E 
CI.IO EH ........LV .........................................-G ............................E 
Cb-I EH ........V .......................W .............c ........M ...................E ..
Cb-2 EH .........V ...........................................-G ............................E 
BeWoCI EH .........V ......................W ...............G ............................E 
CwBLI8 EH .........v ...........................................-G ............................E 
Cx52 EH .........V ...........................................G ............................E 
CI.9 EH .........V ...........................E ........-~3 ..........................E
pCl EH .........V ........................W .............G ........M ...................E ..
consensusD~FKTHVTH~P~SDHEATLRC~ALGFYPAE~TL1~NQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSG~EQRYTCHVQHEGLPKPLTLRW
190 200 210 220 230 240 250 260 270
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274 BJORKMAN & PARHAM
unprecedented genetic polymorphisrn. Currently 20, 40, and 10 antigens of
the HLA-A, B, and C loci have been found that are expressed at significant
frequency within human populations (97). However, these numbers clearly
represent underestimates of the total, since novel alleles continue to be found
as more precise and sensitive methods are applied to HLA typing. As far as
we can tell, diversity in HLA-A,B,C molecules is due solely to amino acid
substitutions in the MHC-encoded heavy chains, with no polymorphism being
contributed by/~2m. There are different alleles of/3zm in mice, but they only
differ by single amino acids from the common form. By contrast, the amino
acid sequences of class I MHC heavy chains exhibit complex patterns of
substitution involving many positions throughout the polypeptide chain (Fig-
ure 4).
HLA-A, B, and C heavy chains are homologous structures, showing only
minor differences in the size of the transmembrane and cytoplasmic domains.
Within the 274 residues of the a~, az, and a3 domains, a total of 165 positions
or 61% of the total are invariant between the 25 HLA-A, 35 HLA-B, and 18
HLA-C sequences that have been determined (Figure 4). These positions
include the invariant glycosylation site at position 86 in al, the cysteines at
positions 101, 164, 203, and 259 that form the disulfide bonds of a2 and a3,
and many of the residues involved in contacting /32m (Figure 4).
Nonclassical class I heavy chains ,encoded by the HLA-E, F, and G genes
share many of these features. For example, consideration of the 165 positions
that are invariant in all 76 HLA-A,B,C sequences shows that 155, 150, and
153 are preserved in HLA-E, F, and G respectively, and that the majority of
differences involve conservative substitutions (Figure 4a, c). Such com-
parisons show that the HLA-E, F, and G gene products have only slightly
diverged from antigen-presenting class I MHC molecules, and that any
functions that these nonclassical class I molecules perform are likely to be
related to the binding of peptides and/or interaction with the TcR complex.
Certain features in the classical class I sequences can be used to distinguish
the products of the HLA-A, B, and C loci. At 31 positions in the amino acid
sequence, products of a single locus are conserved, but differ from products
of the other loci (one position in the leader peptide, two in ~, one in a2, four
in c~3, 13 in the transmembrane sequence, and nine in the cytoplasmic
domains). On the basis of the substitutions at these positions, one can readily
assign sequences to a particular locus. It is of interest that 22 of the 31
"locus-specific" positions are in the transmembrane and cytoplasmic do-
mains. They may represent neutral substitutions acquired since gene duplica-
tion led to the creation of separate HLA-A, B, and C loci, or reflect as-yet-
undiscovered functional differences in the carboxy-terminal regions of their
products.
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CLASS I MHC MOLECULES 275
The a3 Domain
Within the .Xl, o~2, and a3 domains, products of a locus can differ by a single
amino acid or by as many as 30 substitutions. Although the differences are
predominantly found in the al and a2 domains, variation in the a3 domain
may be of importance, especially with respect to CD8 interactions (64, 66).
HLA-B molecules are noticeably homogeneous in the a3 domain, with 25 of
the 34 sequences being identical (Figure 4c). Only three different sub-
stitutions are found, one shared by seven sequences and the other two being
each represented in a single sequence. There is greater variation in HLA-A
locus molecules, substitutions being found at nine positions and allelic prod-
ucts differing by up to seven amino acids. Two observations show functional
effects due to natural substitutions in the a3 domain: first, T cells can
distinguish a substitution of alanine for glutamic acid at position 236 in the
HLA-A2-0ZB subtype (98); second (as discussed above), an alanine to valine
substitution at position 245 in HLA-Aw68.1 and HLA-Aw68.2 reduces the
affinity for CD8 (64). HLA-C molecules show a pattern closer to HLA-A than
to HLA-B in a3, variation occurring at 12 positions and sometimes involving
nonconservative substitutions. A significant locus-specific difference in a3 is
the presence of arginine at position 239 in all HLA-B molecules and of
glycine at this position in all HLA-A and C molecules (Figure 4c, d).
The o~1 and ce2 Domains
From the first comparisons of allelic sequences (23, 99, 100), it was apparent
that exons 2 and 3 encoding the a~ and ce2 domains ,had a higher ratio of
coding to noncoding substitutions than would be expected from random
mutation. These observations argued for diversity being the result of positive
natural selection, which has been confirmed and extended by a subsequent
analysis that has made use of the three-dimensional structure (24). In this
study, Hughes & Nei showed that the ratio of replacement to silent sub-
stitutions at positions involved in the antigen-combining site was significantly
higher than at positions distant from the site. They concluded that class I
MHC polyrnorphism is the result of natural selection and can be explained in
terms of heterozygote advantage. While this idea may be criticized as overly
simplistic (101), there is general agreement that MHC polymorphism results
from positive selection due presumably to advantage from making T cell
responses against particular pathogens. A new ability to respond to a particu-
lar antigen could derive from improvement either in presentation of peptides
or in thymi.c selection of appropriate TcRs.
Analysis of diversity in MHC molecules has been aided by application of
the parameter of variability originally used by Wu & Kabat (102) in compari-
son of Ig sequences. Variability at each position in a set of homologous
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276 BJORKMAN & PARHAM
sequences is defined as the number of different amino acids found at a
particular position divided by the frequency of the most common. Calculation
of variability for all positions in the al, a2, and c~3 domains of HLA-A, B,
and C molecules shows that positions of substitution can be divided into two
groups having variability that is low (<4.0) and high (---4.0) (Table 1). 
division at a variability of 4.0 is somewhat arbitrarily set: it is the value
obtained if two amino acids are present at equal frequency and is also the
maximum variability found amongst the products of six alleles of HLA-AR,
an inactivated gene for which T cell--related selection for diversity no longer
exists and that can serve as a negative control.
Positions of high variability are found in the sequences of all three loci;
however, their number and distribution are very distinct (Table 1, Figure 5).
Nine, fifteen, and five positions of high variability are found respectively for
Table 1 Positions with high variability (> 4.0) in HLA-A,B,C molecules
Variabilitya
Position HLA-A HLA-B HLA-C Potential contact~’
0/I
9 9.1 4.8 10.0 Peptide
24 7.0 Peptide
45 10.0 Peptide
62 13.9 TcR + Peptide
63 4.2 Peptide
67 13.5 Peptide
69 4.8 TcR
70 6.4 Peptide
77 6.2 Peptide
80 7.0 Peptide
81 5.0 Peptide
82 5.5 TcR
0/2
95 5.4 5.0 Peptide
97 5.8 14.0 Peptide
99 5.2 Peptide
114 8.3 6.2 Peptide
116 6.3 15.9 10.2 Peptide
152 5.9 5.5 Peptide
156 8.3 5.6 10.3 Peptide
163 8.1 TcR + Peptide
"Variability defined according to Wu & Kabat (102) index.
See Figure 4 and text for details. The possibility that residue
peptide is discussed in the text.
45 contacts a bound
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20 40 60 80 (3~1
200 220 240 260 I~3
Figure 5 Comparison of variability (V) in amino acid sequence in the extracellular domains 
human class I MHC heavy chains. The variability parameter as defined by Wu & Kabat (102) was
calculated for 25 HLA-A, 35 HLA-B, 18 HLA-C, and 6 HLA-AR sequences; calculations were
made within each group of sequences. Positions with "high variability" (V ->4.0) are shown 
solid black; positions with intermediate variability (3.0 -< V <4.0) are shown in heavy stipple;
positions with low variability (1.0 < V < 3.0) are shown in light stipple, and positions with 
variability (V = 1) are shown in white. The predicted protein sequences of the HLA-AR alleles
were analyzed ignoring the frameshift induced by a single nucleotide deletion. The secondary
structure of each domain is indicated over the top of each diagram;/3 strands are indicated by
arrows, helices by squiggles, and loops by straight lines. The cysteines involved in the conserved
disulfide bond formation are given by S and the conserved glycosylation site by CHO.
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278 BJORKMAN & PARHAM
HLA-A, B, and C with only three positions--9, 116, and 156~being held in
common. The distribution of positions of high variability in HLA-C mole-
cules is more similar to HLA-A, though in other more conserved parts of the
gene, HLA-C sequences are more closely related to HLA-B.
Positions of high variability are those that exhibit the greatest number of
amino acids (three to six), and they tend to have more radical substitution than
positions of low variability, which commonly have just two chemically
similar amino acids. A striking correlation is found between these positions of
high variability and residues proposed to contact peptides and/or T cells on the
basis of the three-dimensional structure (Ref. 27; see Figure 4a and 4b and
Table 1). Of the 20 positions of high variability, 16 can be classified as
peptide-interacting, two fall into the TcR-interacting category, and two are in
intermediate positions where they could interact with peptides and/or TcRs.
Position 45 has high variability, but is located on the fourth/3-strand at the
back of the cq helix, rather than on either the first and second/3-strands or the
c~-helices that form the peptide-binding site. However, this residue was
suggested to be capable of influencing the site since its side chain pointed
toward it (27). Further analysis shows that it forms the base of a hydrophobic
cavity extending from the peptide-binding groove (48). Residues at positions
24, 26, 34, 45, and 67 are important in formation of this cavity. Of these,
glycine 26 and valine 34 are invariant in HLA-A,B,C sequences. The other
three positions exhibit variation that differs dramatically between products of
the three loci. Only two combinations of amino acids are found in HLA-A and
HLA-C molecules, whereas 13 distinct combinations exist in HLA-B mole-
cules (Table 2). Thus there is both conservation and divergence of this pocket
within the products of different class I loci.
Almost all of the peptide- or TcR-interacting residues within the peptide-
binding site show some sequence variability. Notable exceptions are residues
within the a~ domain that form the floor of the site (methionine 5, phenylala-
nine 22, and glycine 26 are completely conserved, and tyrosine 7 and alanine
24 are conserved in all HLA-A molecules). By contrast, the residues on the otz
domain side of the floor are some of the most highly variable within class I
MHC sequences (Table 1). Significant differences in the diversity of the two
helices are seen in comparison of the products of the three loci. The a~ helix
of HLA-C molecules is highly conserved, with nine peptide and TcR-binding
positions that show polymorphism in HLA-A or -B being invariant. By
contrast, HLA-B molecules have the greatest diversity in their oq helices, as
evidenced by the presence of seven positions of high variability, compared to
none in HLA-C and two in HLA-A (Table 1). In the ~1 helix, HLA-A
molecules are intermediate between HLA-B and HLA-C. The situation in the
c~z helix is, however, different: the sequences of HLA-B molecules show less
diversity than HLA-A molecules. For example, 11 of the 20 TcR- and
peptide-binding positions of this helix are conserved amongst 35 HLA-B
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CLASS I MHC MOLECULES 279
Table 2 Diversity in residues~ of the 45 pocket
Position in sequence HLA subtype
24 26 34 45 67
A G V M V all A except A1
A G V M M AI
A G V T F B35, SNA, 51
A G V T S B52
A G V T M B58
A G V M M B57
T G V E C B27
T G V K S B44, 47, 40, 41
T G V M S BI3, 49
S G V E C BI6, 14
S G V T S BI8, 34
S G V E F B8
S G V E Y B7, 42
A G V M S B62
A G V M Y B46
A G V G Y all other C
S G V G Y Cwl, Cw6, JY328
Amino acids indicated by single-letter code.
molecules, compared to 7 of the 20 for 25 HLA-A molecules. In particular,
the amino-te.rminal part of the helical region, residues 139-155, is more
conserved in HLA-B compared to HLA-A sequences. The pattern in the
a2 helix of HLA-C molecules is closer to that of HLA-B than HLA-A mole-
cules. In combining the two c~ helices, there are three distinctive patterns
of diversity, providing further evidence for the functional divergence of
HLA-A, B, and C gene products in their interactions with peptides and
TcRs.
Several interesting features of MHC peptide-binding sites are revealed by
an examination of the HLA-A2 structure and the sequences of other class I
MHC molecules (Figure 4). First, there are many large aromatic residues 
the binding .,site, most notably a number of tyrosine side chains in positions
where they cot]ld potentially interact with bound peptides. Since many of the
tyrosines are: conserved, this is a general feature of class I peptide-binding
grooves, but the significance of the tyrosine side chain for peptide binding is
unknown. (3,ne could speculate that a tyrosine side chain is able to interact
with many of the different types of side chains that would be found on the
high number’ of peptides capable of binding to any given class I molecule, by
virtue of its aromatic moiety that could be involved in hydrophobic in-
teractions, and the polar hydroxyl group that could be involved in hydrogen
bonding. A high percentage of tyrosine side chains has also been noted in
many antibody-combining sites (102a).
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280 BJORKMAN & PARHAM
Another feature conserved in class I peptide-binding sites is a salt bridge
that links the N-terminal end of the a~ helix to the C-terminal end of the a2
helix effectively to hold together one end of the site. The residues involved in
the salt bridge are glutamic acid 55 and arginine 170 (conserved in all human
class I sequences with the exception of HLA-Cw3 and the nonclassical
HLA-E and -G molecules), and its location on the HLA-A2 structure is
highlighted in Figure 2c. The end of the site that contains the salt bridge also
has many large aromatic residues which, together with the residues forming
the salt bridge, effectively make this end of the site more occluded than the
other end. The lack of space at this end of the site is a general feature of class I
MHC peptide-binding sites, since the large residues contributing to it are
mostly conserved (in HLA-A2 these residues are phenylalanine 22, tyrosine
7, and tyrosine 99 on the floor of the site, and tyrosine 59, tyrosine 159, and
tryptophan 167 on the sides of the binding site). Although the helices at the
other end of a class I site are not linked by a salt bridge, this end of the site is
not open, owing to the presence of the conserved tyrosine at position 84,
which points in to block this end of the site.
It is interesting to note that most of the sequence variability within the
peptide binding site falls in positions where side chains point towards the site
(potentially peptide interacting) rather than up into solution (potentially 
interacting). In fact, an examination of the upward-pointing residues in Figure
4 (designated by upward pointing triangles or by diamonds) reveals that, for
many different alleles of HLA molecules, all of the residues pointing up are
the same. Thus, the MHC side chains contacted directly by a TcR recognizing
the peptide-MHC complex would be identical in these cases. The means by
which TcRs distinguish these MHC alleles must be through the indirect
effects that different inward-pointing side chains have on the conformation of
bound peptides and/or the upward pointing MHC residues.
ANTIGENIC PEPTIDE MOTIFS AND THE
CONFORMATION OF BOUND PEPTIDES
The conserved features of class I peptide-binding sites must play some role in
determining what types of peptides will bind to class I MHC molecules, and
their secondary structure conformation. It is not yet possible to predict
accurately from a protein sequence which fragments will be antigenic or what
conformation they would adopt when bound to an MHC molecule. Several
predictive methods have been proposed for the identification of T cell epi-
topes within protein sequences. One method supposes that antigenic peptides
form amphipathic a-helical structures (103), and assumes that the nonpolar
side of the helix contacts the MHC molecule and the polar side faces the
solvent or contacts a TcR. However, an examination of the HLA-A2 structure
clearly suggests that because of the depth of the binding site, a peptide will
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CLASS I MHC MOLECULES 281
contact the MHC molecule on three of its sides, leaving the fourth side
exposed to solvent or in a position to interact with a T cell receptor (27).
There is also no structural reason that peptides need to be amphipathic
structures with a nonpolar side interacting with MHC residues, because the
HLA-A2-binding site contains a number of polar and charged residues, as
well as nonpolar amino acids. Examination of other class I sequences (Figure
4) and sequences of class II MHC molecules aligned to HLA-A2 (69),
suggests that other MHC-binding sites are not particularly hydrophobic either.
Another predictive method to locate which peptides can serve as T cell
immunogen:~ searches for a motif within the primary sequence of a protein
(5). The motif that these authors found by analysis of 57 T cell epitopes 
charged residue or glycine, followed by two or three hydrophobic residues,
ending with a polar residue or glycine. Although this consensus sequence is
quite degenerate, a number of peptides known to be T cell epitopes do not
contain it (104), so it cannot account for all peptides capable of binding 
MHC molecules.
Currently, there are no physical-chemical data regarding the secondary
structures of peptides bound to MHC molecules. Studies to address this
question have been done for peptides that interact with class I1 molecules.
These studies involved assaying the ability of T cells to recognize target cells
pulsed with an altered peptide, and determining the binding ability of the
altered peptide using an in vitro peptide-binding assay. Based on these types
of experiments, an a-helical conformation was suggested for one peptide
.bound to a class II molecule (105), and an extended strand conformation was
suggested for another (106). A study of the HLA-A2 site does not im-
mediately suggest what conformation a specific peptide would adopt when
bound to a class I molecule. However, using computer graphics to dock
peptides into the HLA-A2 site suggests that a peptide in a standard a-helical
conformation is a very tight fit in the binding site, and thus minor movements
of side chains or an even opening up of the site by displacing the a-helices
might be necessary before binding or releasing a peptide in a helical con-
formation. Such a movement need not result in a large structural change, but
could be caused by a flexing or straightening of the a~-~/3-sheet (which has
the standard right-handed twist) resulting in a very slight moving of the
helices. The movement of the MHC helices would have to be slight since the
a: helix is tethered to the B-sheet floor of the site by a disulfide bond. Another
change that might facilitate binding or release of a peptide is breaking the
previously discussed salt bridge linking positions 55 and t70.
WHAT IS SEEN BY A TcR?
Although analysis of the specificity of T cells clearly demonstrated they were
MHC restricted, i.e. they had a dual specificity for both antigen and an MHC
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282 BJORKMAN & PARHAM
molecule (13, 14), the mechanism for this dual recognition remained unclear.
Combining knowledge of the molecular nature of TcRs gained through
biochemical and later molecular cloning studies (107-110) with the structure
of MHC molecules, it is possible to make some predictions about the nature of
the interaction between TcRs and the MHC-peptide complex.
A simple molecular interpretation of MHC-restricted recognition by T cells
would be that TcRs recognize MHC residues as well as peptide residues in the
MHC-peptide complex. Alternatively, it has been proposed that MHC-
restricted TcRs recognize determinants only on the peptide antigen, and that
the apparent dependence upon the correct MHC haplotype for T cell activa-
tion is a consequence of cells with different MHC genotypes selecting,
protecting, and presenting a different set of peptides from any given antigenic
molecule (74, 111). However, since the top surface of a peptide-MHC
complex would probably be relatively fiat, in the sense that the side chains
from the peptide and the side chains on the MHC helices would protrude to
approximately the same height (Figure 6), it seems likely that a TcR that
contacts peptide will inevitably interact with residues on the MHC molecule.
(Of course, the top surface of a peptide-MHC complex would not be com-
pletely flat, since the HLA-A2 helices show some irregularities such as a kink
in the a2 helix at residue 163, and the helices are not perfectly parallel to each
other.) Nevertheless, it would appear that a TcR recognizing the top surface
of the complex cannot avoid making direct contact with side chain atoms from
the MHC molecule as well as the peptide.
A Model for How TcRs Bind to the Peptide-MHC Complex
Models proposing how TcRs might bind to their ligands (2, 112, 113) have
used what is known structurally about antibodies to provide a first order
model for TcR structure. Amino acid sequence comparisons suggest that TcR
variable (V) regions are folded into/3-sandwich structures resembling Ig 
regions (109, 110, 114). Antibody V domains have a conserved mode 
interaction so that the hypervariable loops forming the antigen-binding site are
found in the same relative positions with respect to each other (115). A study
of Ig sequences and structures has identified conserved amino acids that are
critical for maintaining the V region’s contact surface, and most of these
amino acids are found in analogous positions in TcR V region sequences
(112, 116). It is therefore likely that TcR V domains will not only fold into
tertiary structures similar to antibody V regions, but that the chain pairing and
resulting combining sites of TcRs will also be similar to those described for
antibodies (112). From studies of the crystal structures of protein antigen-
antibody complexes (117-119), it has been learned that the antibody-ligand
interface is an area of about 25 × 30 .~. The antigenic determinant is made up
of amino acid main chain and side chain atoms from 16-17 residues that are
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not linear in the primary sequence, but brought together by the tertiary
structure of the protein antigen. No major conformational changes take place
in either the antibody or the antigen after complex formation (117-119).
These same principles have been proposed to apply to TcR recognition of
peptide-MHC complexes (120).
Although variability in TcR regions is less localized than in Ig V regions,
hypervariahility is found in the locations corresponding to the three classic Ig
hypervariable regions of complementarity-determining regions (CDRs) (121).
TcR chains, like those of Igs, are assembled by the relatively random joining
of different coding segments (V, D, and J) to constant region genes. The first
and second CDR are encoded within the V gene segment itself, and the third
CDR is formed by the junction of the V gene segment with smaller gene
segments such as the D (diversity) and J (joining) gene segments. A compari-
son of the pattern of diversity in antibodies and TcRs shows that the receptors
have much less variability in their first and second CDRs that do antibodies,
primarily because there are far fewer TcR V gene segments than Ig V gene
segments. 13y contrast, considerably more diversity is concentrated in the TcR
CDR3 or jrtnctional region as compared to Igs (discussed in more detail in
Ref. 2 and iin M. M. Davis, this volume). In order to rationalize the striking
concentration of TcR diversity within the junctional region and relative lack
of diversity elsewhere, it should be r~levant to consider what TcRs are known
to do: namely to recognize a large number of small molecules (i.e. peptides)
embedded in physically larger and much less diverse MHC molecules. The
simplest interpretation of the skewing of diversity in the TcR case toward the
CDR3-equivalent region is that the amino acids in this region are mainly.
interacting with peptide determinants, and that residues within the much less
diverse CDR1- and CDR2-equivalent regions are primarily involved in con-
tacts to MHC determinants.
In antibodies, the first,and second CDRs of one V domain are separated
from their c,ounterparts on the other domain, and the space between them is
occupied by the CDR3 regions from each chain (115). Structural studies 
antibodies complexed with protein antigens have shown that side chains from
all six CDR,,~ contact the antigen, and that the entire interface is a rather fiat
surface with protrusions and depressions in the antibody being com-
plementary to the antigen surface (117-119). When the (hypothetical) 
combining site is compared to the top surface of the MHC-peptide complex
that is its ligand, it is interesting to note that the el-helices that make up the
sides of the MHC peptide-binding site are separated by about the same
distance as ,,;eparates the CDR1 and CDR2 regions of one V domain from
another (18 A). Thus the top surface of an MHC-peptide complex could
interact witl~t the combining site of an Ig-like TcR such that the limited
diversity in the CDRI- and CDR2-equivalent regions on TcR V,~ and Vt~
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contacts the side chains of the MHC a-helices, leaving the centrally located
and very diverse CDR3-equivalent regions to interact with the peptide (Figure
6). The alignment of CDR1 and CDR2 with MHC determinants and CDR3
with peptide determinants agrees with studies correlating TcR sequences with
known antigen and MHC specificities (122-124), as well as site-directed
mutagenesis experiments to test antigen fine specificity (125).
The use of a hypothetical model, for describing the TcR-peptide-MHC
trimolecular complex points out the obvious need for continued structural
work in order to arrive at a complete description of the precise molecular
nature of this interaction. Determination of the crystal structure of a human
class I MHC molecule has allowed us a glimpse of how MHC molecules use
their diversity to bind peptides and present them to T cells. However, the
conformation that antigenic peptides adopt when bound to an MHC molecule
Figure 6 Proposed mode of interaction of TcR (represented at top of figure) with peptide-MHC
complex (bottom of figure). TcRs arc proposed to bind to their ligands with the low diversity
encoded within their CDRI and 2 regions contacting side chains from the MHC c~-helices, and the
high diversity encoded within their CDR3 regions contacting side chains from a bound peptide
(here shown as a hypothetical 12-residue poly valine o~-helix). FabJ539 (147) is used as a model
for a TcR. Molecules are depicted as carbon-o~ backbones, with side chains included in the
regions proposed to interact. Figure modified from Ref. 2 and prepared with the FRODO graphics
program (146).
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is still an open question, which can best be answered by the crystal structures
of one or more specific peptide-MHC complexes. Our present knowledge
would also be greatly enhanced by the determination of a structure of a TcR
alone or as a complex with its peptide-MHC ligand. As methods improve for
production of protein in the quantities required for crystallization, we can look
forward to new crystal structures of and new insight into the molecules
involved in the cellular immune response.
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